Investment Thesis
Caribou Biosciences faces critical fundamental distress with $27.0M annual operating cash burn against only $12.1M cash reserves, yielding approximately 5.4 months of runway. Revenue generation of $2.4M is insufficient to offset $26.3M operating losses, and flat net income growth despite revenue gains signals deteriorating unit economics. Without immediate major financing or dramatic operational improvement, the company faces existential liquidity risk within two quarters.
Strengths
- Zero long-term debt provides balance sheet flexibility
- Excellent short-term liquidity ratios (6.22x current/quick)
- Modest revenue traction ($2.4M) demonstrates early commercialization
Risks
- Critical cash runway of ~5.4 months at current burn rate ($27M annual operating cash outflow vs $12.1M cash)
- Operating losses of $26.3M dwarf $2.4M revenue, yielding -1096% operating margin and -1046% net margin
- Flat net income YoY despite 11.7% revenue growth indicates worsening unit economics and inability to scale profitably
Key Metrics to Watch
- Cash balance and monthly burn rate trajectory
- Quarterly revenue growth and gross margin expansion
- Operating cash flow inflection point
Financial Metrics
Revenue
2.4M
Net Income
-25.1M
EPS (Diluted)
$-0.26
Free Cash Flow
-27.1M
Total Assets
149.0M
Cash
12.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-1,096.4%
Net Margin
-1,046.5%
ROE
-24.6%
ROA
-16.8%
FCF Margin
-1,128.7%
Balance Sheet & Liquidity
Current Ratio
6.22x
Quick Ratio
6.22x
Debt/Equity
0.00x
Debt/Assets
31.5%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T08:55:12.321064 |
Data as of: 2026-03-31 |
Powered by Claude AI